Memantine Ratiopharm

Memantine, the active ingredient in Memantine Ratiopharm, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of Alzheimer’s disease and is prescribed for patients with mild to moderate cognitive impairment.

GNH USA supplies Memantine Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine acts on the glutamatergic pathway and is used in the management of Alzheimer’s disease. - Mild Alzheimer’s disease: may help maintain baseline cognition and daily functioning. - Moderate Alzheimer’s disease: supports cognitive performance and reduces functional decline. - Severe Alzheimer’s disease: provides modest benefit in cognition and behavior.

Memantine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Fatigue: feeling unusually tired.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring immediate medical attention. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic injury: signs of liver dysfunction including jaundice or elevated enzymes.

When prescribing Memantine, clinicians should consider several safety aspects. - Renal impairment: dose adjustment may be required. - History of seizures: monitor closely for neurological events. - Cardiovascular disease: use cautiously in patients with unstable conditions. - Pregnancy: avoid unless the potential benefit outweighs the risk. - Elderly patients: monitor for confusion or worsening cognition. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine can interact with other medications, necessitating careful review.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase neurotoxicity. - Ketamine: additive effects on NMDA receptors can exacerbate CNS depression. - Other NMDA antagonists: concurrent use may lead to excessive blockade.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may diminish the cognitive benefits of memantine. - CNS depressants (e.g., benzodiazepines): can increase sedation and dizziness. - Diuretics: may alter serum concentrations of memantine.